Vancomycin-induced deletion of the methicillin resistance gene mecA in Staphylococcus aureus

The Journal of Antimicrobial Chemotherapy
Rajan P AdhikariGregory M Cook

Abstract

To elucidate factors that contribute to the development of vancomycin resistance in methicillin-resistant Staphylococcus aureus (MRSA). Forty-nine MRSA isolates were subjected to passage selection with vancomycin to isolate mutants with reduced susceptibility to vancomycin. One mutant was chosen for detailed molecular and biochemical characterization. Five vancomycin-resistant mutants (vancomycin MICs, 6-12 mg/L) were obtained in vitro from five MRSA parent isolates. Upon acquisition of vancomycin resistance, all mutants showed a concomitant decrease in oxacillin resistance. In one particular MRSA strain, selection for vancomycin resistance repeatedly produced deletions and rearrangements, including loss of the mecA gene. Pleiotropic phenotypical changes, such as yellow pigment formation, loss of haemolysis, thickened cell wall, increased resistance to lysostaphin and reduced cell wall turnover were observed in this mutant. Acquisition of vancomycin resistance in one MRSA strain triggered mecA deletion suggesting that this deletion, coupled to other rearrangements and/or mutations, may be responsible for the increased vancomycin resistance phenotype.

Citations

Nov 26, 2013·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Jessica K OrtwineMichael J Rybak
Aug 30, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kevin W McConeghyKeith A Rodvold
Apr 7, 2009·Diagnostic Microbiology and Infectious Disease·Dewan Sakhawat BillalNoboru Yamanaka
Apr 1, 2016·Trials·Steven Y C TongUNKNOWN CAMERA2 study group and the Australasian Society for Infectious Diseases Clinical Research Network
Jun 15, 2007·Expert Opinion on Pharmacotherapy·Scott D Pope, Andrew M Roecker
Mar 18, 2011·International Journal of Antimicrobial Agents·A MartinsL Amaral
Jun 30, 2009·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·S MoneckeG Coombs
May 8, 2016·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Sabrina Di GregorioMarta Mollerach
Jan 26, 2017·Scientific Reports·Aihua WangChao Zhuo
Feb 12, 2005·The Journal of Antimicrobial Chemotherapy·Judith N SteenbergenFrancis P Tally
Jan 9, 2020·Microbial Genomics·Stefano G GiulieriDeborah A Williamson
Sep 6, 2005·The Journal of Antimicrobial Chemotherapy·Parham SendiWerner Zimmerli
May 17, 2021·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Warren RoseGeorge Sakoulas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.